ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.164,48
0,95%
S&P 500
5.155,11
0,53%
Dow Jones
38.703,54
0,07%
Euro vs US Dollar
1,07757
0,17%
Bitcoin
63.448,59
-0,87%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Lexaria Bioscience Corporation (LEXX)

  7. Lexaria Bioscience Corporation (LEXX) News

LEXX

Lexaria Bioscience (LEXX)

Lexaria Bioscience Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LEXX
DatumZeitQuelleÜberschriftSymbolFirma
06/03/202412h00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:LEXXLexaria Bioscience Corporation
01/03/202420h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
16/02/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
16/02/202421h47Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:LEXXLexaria Bioscience Corporation
16/02/202412h01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LEXXLexaria Bioscience Corporation
14/02/202420h20Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LEXXLexaria Bioscience Corporation
14/02/202418h00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LEXXLexaria Bioscience Corporation
30/01/202419h51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
29/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LEXXLexaria Bioscience Corporation
24/01/202420h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
24/01/202419h33Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:LEXXLexaria Bioscience Corporation
18/01/202420h38Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LEXXLexaria Bioscience Corporation
12/01/202423h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LEXXLexaria Bioscience Corporation
11/01/202414h30GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter BloodstreamNASDAQ:LEXXLexaria Bioscience Corporation
10/01/202414h45InvestorsHub NewsWireGLP-1: Beyond Diabetes, a Blockbuster Horizon BeckonsNASDAQ:LEXXLexaria Bioscience Corporation
09/01/202414h30GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery PlatformNASDAQ:LEXXLexaria Bioscience Corporation
08/01/202414h45InvestorsHub NewsWireExciting New Cures Possible from GLP-1 Diabetes, Weight-Loss DrugsNASDAQ:LEXXLexaria Bioscience Corporation
04/01/202423h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
11/12/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LEXXLexaria Bioscience Corporation
08/12/202322h31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LEXXLexaria Bioscience Corporation
30/11/202322h14Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:LEXXLexaria Bioscience Corporation
20/11/202323h16Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LEXXLexaria Bioscience Corporation
03/11/202318h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
01/11/202318h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LEXXLexaria Bioscience Corporation
01/11/202313h45InvestorsHub NewsWireGet Ready for Next Generation of Diabetes, Weight-Management DrugsNASDAQ:LEXXLexaria Bioscience Corporation
01/11/202313h30GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug SpaceNASDAQ:LEXXLexaria Bioscience Corporation
31/10/202313h31GlobeNewswire Inc.Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 DrugsNASDAQ:LEXXLexaria Bioscience Corporation
30/10/202317h47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LEXXLexaria Bioscience Corporation
30/10/202313h45InvestorsHub NewsWireCan Diabetes, Weight-Loss Drugs Get Even Better?NASDAQ:LEXXLexaria Bioscience Corporation
18/10/202318h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LEXXLexaria Bioscience Corporation
 Showing the most relevant articles for your search:NASDAQ:LEXX

Kürzlich von Ihnen besucht

TG
DTE
Deutsche Telekom
NASDAQ
AMZN
Amazon.com
TG
ALV
Allianz
COIN
SOLUSD
Solana
CCOM
US500
US 500
AMEX
XLV
Health Care Select Sector
NASDAQ
NVDA
NVIDIA
TG
MBG
MercedesBenz
USOTC
RHHBY
Roche (QX)
USOTC
DTEGY
Deutsche Telekom (QX)
TG
CBK
Commerzbank
NASDAQ
TSLA
Tesla
USOTC
BASFY
BASF (QX)
NYSE
KO
Coca Cola
TG
NOV
Novo Nordisk
USOTC
ADDYY
Adidas (QX)
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten